Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) overview
Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or unknown causes. Some common types of ILD are sarcoidosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and eosinophilic pneumonia. ILD can cause symptoms such as shortness of breath, dry cough, fatigue, and chest pain. The diagnosis of ILD is based on medical history, physical examination, chest imaging, lung function tests, and sometimes lung biopsy. The treatment of ILD depends on the specific type and cause of the disease, but may include corticosteroids, immunosuppressants, antifibrotics, oxygen therapy, pulmonary rehabilitation, or lung transplantation. ILD is a chronic and progressive condition that can affect the quality of life and survival of patients.
For a complete picture of PTSR and LoA scores for drugs in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
